Companies / Information Technology
ZBRA
Zebra Technologies
Electronic Equipment & Instruments
Electronic Equipment & InstrumentsAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health60
Growth36
Profitability48
Cash generation81
Balance sheet52
Dilution control81
Key ratios and five-year financials
Latest quarter revenue YoY (2026-10-03)22.3%Revenue growth (FY)8.3%Revenue CAGR (3y)-2.3%Gross margin48.1%Operating margin13.0%Net margin7.8%Free cash flow margin15.4%R&D / revenue11.0%Stock comp / revenue3.0%Net debt / operating cash flow2.59xCurrent ratio0.97Diluted share count change-1.3%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $5.6B | $5.8B | $4.6B | $5.0B | $5.4B |
| Gross profit | $2.6B | $2.6B | $2.1B | $2.4B | $2.6B |
| Operating income | $979M | $529M | $481M | $742M | $700M |
| Net income | $837M | $463M | $296M | $528M | $419M |
| Operating cash flow | $1.1B | $488M | -$4M | $1.0B | $917M |
| Capital expenditure | $59M | $75M | $87M | $59M | $86M |
| Free cash flow | $1.0B | $413M | -$91M | $954M | $831M |
| R&D | $567M | $570M | $519M | $563M | $593M |
| Stock-based comp | $76M | $88M | $55M | $89M | $163M |
| Buybacks | $57M | $751M | $52M | $47M | $587M |
| Cash | $332M | $105M | $137M | $901M | $125M |
| Total debt | $991M | $2.0B | $2.2B | $2.2B | $2.5B |
| Equity | $3.0B | $2.7B | $3.0B | $3.6B | $3.6B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.